JPMorgan lowered the firm’s price target on Caris Life Sciences (CAI) to $35 from $40 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q4 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $35 from $42 at Citi
- Caris Life Sciences reports Q4 EPS 28c, consensus 10c
- Caris Life Sciences sees 2026 revenue $1.0B-$1.02B, consensus $979.7M
- Caris Life Sciences initiated with an Outperform at Baird
- Caris Life Sciences sees Q4 revenue $281M, consensus $204.31M